Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies

• Published in: PloS one 2014-03, Vol.9 (3), p.e91461-e91461
• Main Authors: Shen, Kaini, Xu, Gufeng, Wu, Qing, Zhou, Daobin, Li, Jian
• Format: Article
• Language: English
• Subjects: Anemia; Arthritis; Arthritis, Rheumatoid - complications; Autoimmune diseases; Autoimmune Diseases - complications; Cancer therapies; Case-Control Studies; Cohort analysis; Cohort Studies; Comorbidity; Development and progression; Disease; Epidemiology; Family medical history; Female; Health aspects; Health risk assessment; Hematology; Hospitals; Humans; Ionizing radiation; Lymphoma; Male; Medical prognosis; Medicine; Meta-analysis; Multiple myeloma; Multiple Myeloma - complications; Population; Rheumatic diseases; Rheumatoid arthritis; Rheumatoid factor; Risk Factors; Studies; Systematic review; Tumor necrosis factor-TNF
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0091461

multiple myeloma is a malignant neoplasm of plasma cells mainly affecting elderly patients. Despite the wealth of information available on therapeutic strategies, the etiology and pathogenesis of myeloma remain unclear. In the current study, a meta-analysis was conducted to assess the possible association between rheumatoid arthritis and myeloma. a literature search was conducted with PubMed, EMBASE and Web of Science for relevant studies published by December 25, 2013. Additionally, we searched annual meeting abstracts of the American Society of Hematology from 2004 to 2013. Only original studies that investigated the association between rheumatoid arthritis and myeloma were included. In total, 8 case-control and 10 cohort studies were identified for analysis. the meta-estimate of the association between rheumatoid arthritis and myeloma was 1.14 (95% CI, 0.97-1.33) overall, with significant heterogeneity among studies. The relationship between myeloma and other autoimmune diseases was additionally examined from available data. Our results showed that myeloma risk is increased 1.31 to 1.65-fold in pernicious anemia and 1.36 to 2.30-fold in ankylosing spondylitis patients. Rheumatoid arthritis does not appear to alter the risk of myeloma, while between-study heterogeneity analyses suggest caution in the interpretation of results. Pernicious anemia and ankylosing spondylitis may be potential risk factors for myeloma development. Future large-scale epidemiological studies with reliable exposure biomarkers are necessary to establish the possible contribution of autoimmune disorders to multiple myeloma.